

32. (amended) A method for modulating excitatory synapse function in a cell or group of cells, the method comprising administering to the cells a modulation effective amount of the SYNGAP of claim 21 [any one of claims 21 to 24] or fragment or derivative thereof.

34. (amended) A method for treating a disorder associated with mammalian GTPase Activating Protein at Synapses (SYNGAP) comprising administering to a patient suffering from or susceptible to such disorder an effective amount of an isolated polynucleotide of claim 1 [any one of claims 1 to 20] or fragment or derivative thereof.

35. (amended) A method for treating a disorder associated with mammalian GTPase Activating Protein at Synapses (SYNGAP) comprising administering to a patient suffering from or susceptible to such disorder an effective amount of an isolated SYNGAP of claim 21 [any one of claims 21 to 24] or fragment or derivative thereof.

62. (amended) An amino acid sequence detected by the method of claim 56 [any of the methods of claims 56 to 61].

63. (amended) A method for detecting excitatory synapses in a cell or group of cells, the method comprising contacting cells or a group of cells with the antibody or antigen-binding fragment of claim 26 [any one of claims 26 to 29] under condition sufficient to detect the excitatory synapses in the cells or group of cells.

REMARKS

For the sole purpose of reducing initial USPTO claim fees, claims 33, 36-43, 46, 47, 49-53, 55 and 57-61 have been cancelled without prejudice, and claims 20, 31, 32, 34, 35, 62 and 63 have been amended. The present submission should therefor